![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LAMA1 |
Gene summary for LAMA1 |
![]() |
Gene information | Species | Human | Gene symbol | LAMA1 | Gene ID | 284217 |
Gene name | laminin subunit alpha 1 | |
Gene Alias | LAMA | |
Cytomap | 18p11.31 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P25391 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284217 | LAMA1 | AEH-subject3 | Human | Endometrium | AEH | 4.09e-18 | 5.42e-01 | -0.2576 |
284217 | LAMA1 | AEH-subject5 | Human | Endometrium | AEH | 4.95e-15 | 5.41e-01 | -0.2953 |
284217 | LAMA1 | EEC-subject1 | Human | Endometrium | EEC | 3.16e-09 | 3.86e-01 | -0.2682 |
284217 | LAMA1 | EEC-subject2 | Human | Endometrium | EEC | 5.02e-12 | 3.82e-01 | -0.2607 |
284217 | LAMA1 | EEC-subject5 | Human | Endometrium | EEC | 5.80e-08 | 3.72e-01 | -0.249 |
284217 | LAMA1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.26e-04 | 5.60e-03 | -0.1883 |
284217 | LAMA1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.00e-09 | 4.00e-01 | -0.1934 |
284217 | LAMA1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 4.14e-03 | -1.83e-03 | -0.1916 |
284217 | LAMA1 | P2T-E | Human | Esophagus | ESCC | 1.53e-19 | 3.30e-01 | 0.1177 |
284217 | LAMA1 | P4T-E | Human | Esophagus | ESCC | 2.45e-12 | 3.10e-01 | 0.1323 |
284217 | LAMA1 | P5T-E | Human | Esophagus | ESCC | 2.28e-35 | 5.69e-01 | 0.1327 |
284217 | LAMA1 | P11T-E | Human | Esophagus | ESCC | 1.20e-09 | 4.28e-01 | 0.1426 |
284217 | LAMA1 | P12T-E | Human | Esophagus | ESCC | 3.87e-34 | 6.73e-01 | 0.1122 |
284217 | LAMA1 | P15T-E | Human | Esophagus | ESCC | 1.67e-14 | 3.46e-01 | 0.1149 |
284217 | LAMA1 | P22T-E | Human | Esophagus | ESCC | 1.13e-16 | 3.79e-01 | 0.1236 |
284217 | LAMA1 | P26T-E | Human | Esophagus | ESCC | 2.39e-24 | 4.16e-01 | 0.1276 |
284217 | LAMA1 | P31T-E | Human | Esophagus | ESCC | 1.23e-20 | 4.85e-01 | 0.1251 |
284217 | LAMA1 | P32T-E | Human | Esophagus | ESCC | 2.06e-08 | 2.00e-01 | 0.1666 |
284217 | LAMA1 | P37T-E | Human | Esophagus | ESCC | 3.50e-19 | 4.50e-01 | 0.1371 |
284217 | LAMA1 | P42T-E | Human | Esophagus | ESCC | 2.79e-04 | 1.52e-01 | 0.1175 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00074099 | Prostate | BPH | axonogenesis | 98/3107 | 418/18723 | 1.68e-04 | 1.45e-03 | 98 |
GO:00303237 | Prostate | BPH | respiratory tube development | 48/3107 | 181/18723 | 4.65e-04 | 3.33e-03 | 48 |
GO:00303247 | Prostate | BPH | lung development | 47/3107 | 177/18723 | 5.13e-04 | 3.63e-03 | 47 |
GO:00308593 | Prostate | BPH | polarized epithelial cell differentiation | 11/3107 | 24/18723 | 7.76e-04 | 5.10e-03 | 11 |
GO:00487543 | Prostate | BPH | branching morphogenesis of an epithelial tube | 40/3107 | 151/18723 | 1.35e-03 | 8.10e-03 | 40 |
GO:00350887 | Prostate | BPH | establishment or maintenance of apical/basal cell polarity | 17/3107 | 49/18723 | 1.60e-03 | 9.32e-03 | 17 |
GO:00612457 | Prostate | BPH | establishment or maintenance of bipolar cell polarity | 17/3107 | 49/18723 | 1.60e-03 | 9.32e-03 | 17 |
GO:00605415 | Prostate | BPH | respiratory system development | 50/3107 | 203/18723 | 2.09e-03 | 1.17e-02 | 50 |
GO:00611624 | Prostate | BPH | establishment of monopolar cell polarity | 10/3107 | 24/18723 | 3.21e-03 | 1.67e-02 | 10 |
GO:00451977 | Prostate | BPH | establishment or maintenance of epithelial cell apical/basal polarity | 15/3107 | 44/18723 | 3.59e-03 | 1.83e-02 | 15 |
GO:00613393 | Prostate | BPH | establishment or maintenance of monopolar cell polarity | 10/3107 | 25/18723 | 4.57e-03 | 2.19e-02 | 10 |
GO:0035272 | Prostate | BPH | exocrine system development | 15/3107 | 45/18723 | 4.57e-03 | 2.19e-02 | 15 |
GO:00604413 | Prostate | BPH | epithelial tube branching involved in lung morphogenesis | 11/3107 | 29/18723 | 4.82e-03 | 2.29e-02 | 11 |
GO:00350892 | Prostate | BPH | establishment of apical/basal cell polarity | 9/3107 | 22/18723 | 5.92e-03 | 2.73e-02 | 9 |
GO:0007431 | Prostate | BPH | salivary gland development | 12/3107 | 34/18723 | 6.45e-03 | 2.91e-02 | 12 |
GO:00017386 | Prostate | BPH | morphogenesis of a polarized epithelium | 25/3107 | 94/18723 | 9.36e-03 | 3.98e-02 | 25 |
GO:0007435 | Prostate | BPH | salivary gland morphogenesis | 11/3107 | 32/18723 | 1.11e-02 | 4.55e-02 | 11 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541625 | Endometrium | AEH | Viral myocarditis | 27/1197 | 60/8465 | 6.98e-09 | 1.13e-07 | 8.30e-08 | 27 |
hsa0451015 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
hsa051466 | Endometrium | AEH | Amoebiasis | 29/1197 | 102/8465 | 1.22e-04 | 1.10e-03 | 8.06e-04 | 29 |
hsa05416111 | Endometrium | AEH | Viral myocarditis | 27/1197 | 60/8465 | 6.98e-09 | 1.13e-07 | 8.30e-08 | 27 |
hsa0451016 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
hsa0514613 | Endometrium | AEH | Amoebiasis | 29/1197 | 102/8465 | 1.22e-04 | 1.10e-03 | 8.06e-04 | 29 |
hsa0541626 | Endometrium | EEC | Viral myocarditis | 28/1237 | 60/8465 | 2.81e-09 | 5.77e-08 | 4.30e-08 | 28 |
hsa0451024 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
hsa0514622 | Endometrium | EEC | Amoebiasis | 28/1237 | 102/8465 | 5.23e-04 | 3.83e-03 | 2.85e-03 | 28 |
hsa0514516 | Endometrium | EEC | Toxoplasmosis | 28/1237 | 112/8465 | 2.48e-03 | 1.48e-02 | 1.11e-02 | 28 |
hsa0541635 | Endometrium | EEC | Viral myocarditis | 28/1237 | 60/8465 | 2.81e-09 | 5.77e-08 | 4.30e-08 | 28 |
hsa0451034 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
hsa0514632 | Endometrium | EEC | Amoebiasis | 28/1237 | 102/8465 | 5.23e-04 | 3.83e-03 | 2.85e-03 | 28 |
hsa0514517 | Endometrium | EEC | Toxoplasmosis | 28/1237 | 112/8465 | 2.48e-03 | 1.48e-02 | 1.11e-02 | 28 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa052229 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0522216 | Esophagus | ESCC | Small cell lung cancer | 69/4205 | 92/8465 | 5.40e-07 | 3.85e-06 | 1.97e-06 | 69 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LAMA1 | SNV | Missense_Mutation | novel | c.1082N>A | p.Cys361Tyr | p.C361Y | P25391 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
LAMA1 | SNV | Missense_Mutation | novel | c.1870N>A | p.Glu624Lys | p.E624K | P25391 | protein_coding | tolerated(0.21) | possibly_damaging(0.516) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
LAMA1 | SNV | Missense_Mutation | c.1211N>T | p.Ser404Phe | p.S404F | P25391 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
LAMA1 | SNV | Missense_Mutation | novel | c.3229T>G | p.Cys1077Gly | p.C1077G | P25391 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LAMA1 | SNV | Missense_Mutation | c.3025N>T | p.Pro1009Ser | p.P1009S | P25391 | protein_coding | tolerated(0.09) | possibly_damaging(0.671) | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | ||
LAMA1 | SNV | Missense_Mutation | novel | c.8473N>A | p.Gly2825Arg | p.G2825R | P25391 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LAMA1 | SNV | Missense_Mutation | c.484C>G | p.Arg162Gly | p.R162G | P25391 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
LAMA1 | SNV | Missense_Mutation | novel | c.8971C>G | p.Leu2991Val | p.L2991V | P25391 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
LAMA1 | SNV | Missense_Mutation | rs756248044 | c.7609N>T | p.Arg2537Cys | p.R2537C | P25391 | protein_coding | deleterious(0) | possibly_damaging(0.765) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LAMA1 | SNV | Missense_Mutation | rs777131128 | c.6383N>A | p.Arg2128Gln | p.R2128Q | P25391 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
284217 | LAMA1 | DRUGGABLE GENOME | CHEMBL2095222 | OCRIPLASMIN |
Page: 1 |